NewslettersDermal Cell News Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy By Laurisa Dohm - January 23, 2023 0 Evaxion Biotech A/S announced that the FDA has granted fast track designation for their personalized cancer therapy, EVX-01, in combination with KEYTRUDA® for patients with metastatic melanoma. [Evaxion Biotech A/S] Press Release